CY1111170T1 - Ενωσεις διαρυλ αιθερα ουριας - Google Patents

Ενωσεις διαρυλ αιθερα ουριας

Info

Publication number
CY1111170T1
CY1111170T1 CY20111100140T CY111100140T CY1111170T1 CY 1111170 T1 CY1111170 T1 CY 1111170T1 CY 20111100140 T CY20111100140 T CY 20111100140T CY 111100140 T CY111100140 T CY 111100140T CY 1111170 T1 CY1111170 T1 CY 1111170T1
Authority
CY
Cyprus
Prior art keywords
compounds
urine
universal business
business essential
preparation
Prior art date
Application number
CY20111100140T
Other languages
English (en)
Inventor
Lorraine Kathleen Fay
Douglas Scott Johnson
Scott Edward Lazerwith
Mark Anthony Morris
Lijuan Jane Wang
Marvin Jay Meyers
Suzanne Ross Kesten
Cory Michael Stiff
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39314409&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111170(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of CY1111170T1 publication Critical patent/CY1111170T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Η παρούσα εφεύρεση αφορά Ενώσεις του Τύπου (I): ή φαρμακευτικώς αποδεκτό άλας αυτών, μεθόδους για την παρασκευή των Ενώσεων, ενδιάμεσα που χρησιμοποιούνται στην παρασκευή των Ενώσεων, συνθέσεις που περιέχουν τις Ενώσεις και χρήσεις των Ενώσεων στην θεραπεία ασθενειών ή καταστάσεων που συνδυάζονται με δραστικότητα υδρολάσης αμιδίου λιπαρού οξέος (FAAH).
CY20111100140T 2006-10-18 2011-02-08 Ενωσεις διαρυλ αιθερα ουριας CY1111170T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82996606P 2006-10-18 2006-10-18
US96521007P 2007-08-17 2007-08-17
EP07848827A EP2076508B1 (en) 2006-10-18 2007-10-05 Biaryl ether urea compounds

Publications (1)

Publication Number Publication Date
CY1111170T1 true CY1111170T1 (el) 2015-06-11

Family

ID=39314409

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100140T CY1111170T1 (el) 2006-10-18 2011-02-08 Ενωσεις διαρυλ αιθερα ουριας

Country Status (39)

Country Link
US (1) US8044052B2 (el)
EP (1) EP2076508B1 (el)
JP (1) JP4434313B2 (el)
KR (1) KR101181194B1 (el)
CN (1) CN101595102B (el)
AP (1) AP2780A (el)
AR (1) AR063331A1 (el)
AT (1) ATE493984T1 (el)
AU (1) AU2007311591B2 (el)
BR (1) BRPI0717596B8 (el)
CA (1) CA2663984C (el)
CL (1) CL2007003000A1 (el)
CR (2) CR10701A (el)
CY (1) CY1111170T1 (el)
DE (1) DE602007011793D1 (el)
DK (1) DK2076508T3 (el)
EA (1) EA015488B1 (el)
ES (1) ES2357340T3 (el)
GE (1) GEP20125425B (el)
HK (1) HK1139652A1 (el)
HN (1) HN2007000407A (el)
HR (1) HRP20110158T1 (el)
IL (1) IL197664A (el)
MA (1) MA30801B1 (el)
ME (1) ME01308B (el)
MX (1) MX2009004233A (el)
MY (1) MY145460A (el)
NO (1) NO342266B1 (el)
NZ (1) NZ575624A (el)
PE (1) PE20081265A1 (el)
PL (1) PL2076508T3 (el)
PT (1) PT2076508E (el)
RS (2) RS20090154A (el)
SI (1) SI2076508T1 (el)
TN (1) TN2009000138A1 (el)
TW (1) TWI404715B (el)
UY (1) UY30649A1 (el)
WO (1) WO2008047229A2 (el)
ZA (1) ZA200902548B (el)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007008134A (es) 2004-12-30 2008-01-16 Johnson & Johnson Piperacinil y piperadinil ureas como moduladores de la amida hidrolasa de acido graso.
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
DK2076508T3 (da) 2006-10-18 2011-02-21 Pfizer Prod Inc Biaryl-ether-urinstof-forbindelser
AR072249A1 (es) 2008-04-09 2010-08-18 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de acido graso. usos. metodos.
CA2719785A1 (en) * 2008-04-17 2009-10-22 Pfizer Inc. Ether benzylidene piperidine aryl carboxamide compounds
EP2276738A1 (en) * 2008-04-17 2011-01-26 Pfizer Inc. Ether benzylidene piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors
WO2009127948A1 (en) * 2008-04-17 2009-10-22 Pfizer Inc. 4- [3- (aryloxy) benzylidene] -3-methyl piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors
US20110053950A1 (en) * 2008-04-17 2011-03-03 Pfizer, Inc. 4-benzylidene-3-methylpiperidine aryl carboxamide compounds useful as faah inhibitors
CA2716886A1 (en) * 2008-04-17 2009-10-22 Pfizer Inc. 4-[3-(aryloxy)benzylidene]-3-methyl piperidine aryl carboxamide compounds
WO2010068452A1 (en) 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2010068453A1 (en) 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2010064597A1 (ja) * 2008-12-01 2010-06-10 武田薬品工業株式会社 ピペリジン誘導体
DK2385938T3 (en) 2009-01-12 2015-04-27 Pfizer Ltd Sulfonamidderivater
EP2416660B1 (en) 2009-04-07 2014-07-02 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
AU2010234449A1 (en) 2009-04-07 2011-11-03 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US9062116B2 (en) 2009-04-23 2015-06-23 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
US8927551B2 (en) 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8765735B2 (en) 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US9149465B2 (en) 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
WO2010141809A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
AU2010293429B2 (en) 2009-09-09 2015-12-17 Sumitomo Dainippon Pharma Co., Ltd. 8-oxodihydropurine derivative
WO2011077313A1 (en) 2009-12-22 2011-06-30 Pfizer Inc. Piperidinecarboxamides as mpges - 1 inhibitors
US20130150346A1 (en) 2010-01-08 2013-06-13 Quest Ventures Ltd. Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
CN102834401B (zh) 2010-02-03 2016-08-24 无限药品股份有限公司 脂肪酸酰胺水解酶抑制剂
CA2789606A1 (en) 2010-02-25 2011-09-01 Pfizer Limited Peptide analogues as opioid receptor agonists
US20130224151A1 (en) 2010-03-31 2013-08-29 United States Of America Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
ES2526675T3 (es) 2010-07-09 2015-01-14 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
JP5830534B2 (ja) 2010-07-09 2015-12-09 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化合物
CA2801032A1 (en) 2010-07-12 2012-01-19 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
EP2593431B1 (en) 2010-07-12 2014-11-19 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
JP2013536165A (ja) 2010-07-12 2013-09-19 ファイザー・リミテッド 痛みの処置のためのｎａｖ１．７阻害薬としてのスルホンアミド誘導体
CA2804716A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
ES2526541T3 (es) 2010-07-12 2015-01-13 Pfizer Limited N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
MX2013011612A (es) 2011-04-05 2013-10-17 Pfizer Ltd Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasa relacionados con tropomiosina.
ES2564366T3 (es) 2011-07-13 2016-03-22 Pfizer Limited Análogos de encefalina
WO2013042139A1 (en) * 2011-09-23 2013-03-28 Advinus Therapeutics Limited Amide compounds, compositions and applications thereof
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
AU2012328034B2 (en) 2011-10-26 2015-04-23 Pfizer Limited (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
ES2648901T3 (es) 2011-10-28 2018-01-08 Inhibitaxin Limited Derivados de piridazina útiles en terapia
JP6058023B2 (ja) 2011-12-15 2017-01-11 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ スルホンアミド誘導体
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
US20150291514A1 (en) 2012-01-04 2015-10-15 Pfizer Limted N-Aminosulfonyl Benzamides
ES2548228T3 (es) 2012-02-03 2015-10-15 Pfizer Inc Derivados de bencimidazol e imidazopiridina como moduladores de canal de sodio
EP2903989A1 (en) 2012-10-04 2015-08-12 Pfizer Limited Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
JP2015531393A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ トロポミオシン関連キナーゼ阻害剤
JP2015531395A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ ピロロ［３，２−ｃ］ピリジントロポミオシン関連キナーゼ阻害剤
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
LT3319959T (lt) 2015-07-06 2021-12-27 Alkermes, Inc. Histono deacetilazės hetero-halogeno inhibitoriai
SG11201906164RA (en) 2017-01-11 2019-08-27 Rodin Therapeutics Inc Bicyclic inhibitors of histone deacetylase
US11040956B2 (en) * 2017-06-30 2021-06-22 Amgen Inc. Synthesis of omecamtiv mecarbil
JP7152471B2 (ja) 2017-08-07 2022-10-12 ロダン・セラピューティクス，インコーポレーテッド ヒストン脱アセチル化酵素の二環阻害剤
EA039850B1 (ru) * 2018-04-30 2022-03-21 Эмджен Инк. Синтез омекамтива мекарбила
EP3841096A4 (en) * 2018-08-24 2022-05-18 Sunshine Lake Pharma Co., Ltd. PYRIDINYLMETHYLENEPIPERIDEINDIVATES AND THEIR USES
KR20240046737A (ko) * 2021-08-04 2024-04-09 재즈 파마슈티칼즈 아일랜드 리미티드 외상후 스트레스 장애의 치료 방법

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB138405A (en) 1919-01-16 1920-02-12 Thomas Thompson Improvements in or relating to suction or delivery valves for pumps
GB1138405A (en) 1966-12-28 1969-01-01 Ici Ltd Morpholine derivatives
US3576810A (en) 1968-06-20 1971-04-27 Robins Co Inc A H 1-substituted-3-(-4)-aroylpiperidines
GB1260886A (en) 1969-06-20 1972-01-19 Ici Ltd Process for aryloxymethylmorpholine derivatives
BE758766A (fr) 1969-11-17 1971-05-10 Ici Ltd Nouveaux derives de la morpholine et de la
BE759013R (fr) 1969-11-17 1971-05-17 Ici Ltd Derives de la
US4116665A (en) 1976-04-02 1978-09-26 Eli Lilly And Company Method of regulating the growth of aquatic weeds with pyridine derivatives
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
GB8424979D0 (en) 1984-10-03 1984-11-07 Wyeth John & Brother Ltd Benzenesulphonamide derivatives
GB2167407B (en) 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JPH07121938B2 (ja) 1991-12-18 1995-12-25 シェリング・コーポレーション 窒素含有６員複素環で置換されたイミダゾイルアルキル化合物
DE4326344A1 (de) 1993-08-05 1995-02-09 Thomae Gmbh Dr K Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
AU7823894A (en) 1993-08-27 1995-03-21 Vrije Universiteit New imidazole derivatives having agonistic or antagonistic activity on the histamine h3 receptor
HUP9602489A3 (en) 1995-01-11 1998-01-28 Samjin Pharm Co Ltd Piperazine derivatives, process for producing them and pharmaceutical compositions containing them
US6271015B1 (en) 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
GB9526560D0 (en) 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
FR2744449B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
US6184242B1 (en) 1997-09-04 2001-02-06 Syntex Usa (Llc) 2-(substituted-phenyl)amino-imidazoline derivatives
JP4778612B2 (ja) 1998-04-01 2011-09-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐｄｅｉｖ阻害ピリジン誘導体
ATE260238T1 (de) 1998-12-29 2004-03-15 Upjohn Co Verfahren zur herstellung von arylethern
PE20001566A1 (es) 1999-03-26 2001-02-05 Ucb Sa Piperazinas 1,4-sustituidas, piperidinas 1,4-sustituidas y 4-alquilidenilpiperidinas 1-sustituidas
IL145661A0 (en) 1999-03-31 2002-06-30 Janssen Pharmaceutica Nv Pregelatinized starch in a controlled release formulation
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
AU7556800A (en) 1999-10-07 2001-05-10 Tadeka Chemical Industries, Ltd. Amine derivatives
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
HUP0204272A3 (en) 2000-01-18 2005-03-29 Pfizer Prod Inc Corticotropin releasing factor antagonists, pharmaceutical compositions containing them and their use
AP2002002596A0 (en) 2000-02-11 2002-09-30 Vertex Pharma Piperazine and piperidine derivatives.
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
BR0108965A (pt) 2000-03-03 2002-11-26 Ortho Mcneil Pharm Inc Derivados de 3-(diarilmetileno)-8-azabiciclo[3,2,1]octano
JP2001303987A (ja) 2000-04-21 2001-10-31 Toyota Motor Corp 筒内噴射式内燃機関のスロットル制御装置
AU2001264376A1 (en) 2000-06-15 2001-12-24 Chaconne Nsi Co., Ltd. Urea derivative useful as an anti-cancer agent and process for preparing same
US20020183316A1 (en) 2000-10-27 2002-12-05 Kevin Pan Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
CA2437353A1 (en) 2001-02-08 2002-08-15 Nps Pharmaceuticals, Inc. Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same
EP1406889A2 (en) 2001-07-09 2004-04-14 Pharmacia Italia S.p.A. Interaction inhibitors of tcf-4 with beta-catenin
AU2002363236A1 (en) 2001-10-30 2003-05-12 Millennium Pharmaceuticals, Inc. Compounds, pharmaceutical compositions and methods of use therefor
US20040034101A1 (en) 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
JP3865626B2 (ja) 2001-11-08 2007-01-10 株式会社ベステックスキョーエイ パイプ部材
FR2833261B1 (fr) 2001-12-06 2004-07-02 Yang Ji Chemical Company Ltd Nouveaux composes inhibiteurs specifiques de la phospholipase a2 secretee non pancreatique humaine du groupe ii
US20040063726A1 (en) 2002-02-08 2004-04-01 Artman Linda D Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same
PL212089B1 (pl) 2002-03-13 2012-08-31 Janssen Pharmaceutica Nv Związki heterocykliczne jako inhibitory deacetylazy histonowej, kompozycja farmaceutyczna je zawierająca, ich zastosowanie, sposób wytwarzania, sposób wykrywania lub identyfikacji HDAC oraz kompozycja
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
WO2003080060A1 (en) 2002-03-20 2003-10-02 Schering Aktiengesellschaft Substituted piperazine antithrombotic pai-1 inhibitors
TWI283241B (en) 2002-05-29 2007-07-01 Tanabe Seiyaku Co Novel piperidine compound
EP1572311A4 (en) 2002-10-21 2007-12-12 Janssen Pharmaceutica Nv ASSAY FOR DETERMINING THE ACTIVITY OF FATTY ACID AMIDHYDROLASE
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
KR20050118708A (ko) 2003-04-03 2005-12-19 메르크 파텐트 게엠베하 혈전-색전 질환의 치료에서 응고 인자 ｘａ의 저해제로서사용하기 위한피롤리디노-１,２-디카르복시-１-(페닐아미드)-２-(４-(３-옥소-모르폴리노-４-일)-페닐아미드) 유도체 및 관련화합물
SE0301442D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations therof and uses thereof
SE0301443D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
GB0325287D0 (en) 2003-10-29 2003-12-03 Merck Sharp & Dohme Therapeutic agents
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EP1689739B1 (en) * 2003-12-03 2016-03-30 YM BioSciences Australia Pty Ltd Azole-based kinase inhibitors
EP1737853A1 (en) 2004-02-03 2007-01-03 Janssen Pharmaceutica N.V. 3-(diheteroarylmethylene)-8-azabicyclo¬3.2.1|octane and 3-((aryl)(heteroaryl)methylene)-8-azabicyclo¬3.2.1|octane derivatives
WO2005100356A1 (en) * 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibitors of akt activity
US20080103209A1 (en) 2004-04-23 2008-05-01 The Regents Of The University Of California Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists
SE0401343D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine N oxide as scaffold
DE602005011279D1 (de) 2004-06-04 2009-01-08 Arena Pharm Inc Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2580845A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
DE102004045796A1 (de) 2004-09-22 2006-03-23 Merck Patent Gmbh Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung
WO2006035303A1 (en) 2004-09-29 2006-04-06 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US7491720B2 (en) 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
EP1655297A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1657241A1 (en) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
GT200500375A (es) 2004-12-20 2006-11-28 Derivados de piperidina y su uso como agentes antiinflamatorios
EP1831164A1 (en) 2004-12-24 2007-09-12 AstraZeneca AB Heterocyclic compounds as ccr2b antagonists
JP4980928B2 (ja) 2004-12-24 2012-07-18 プロシディオン・リミテッド Ｇタンパク質共役受容体（ｇｐｒ１１６）作動薬および肥満および糖尿病治療のためのその使用
MX2007008134A (es) * 2004-12-30 2008-01-16 Johnson & Johnson Piperacinil y piperadinil ureas como moduladores de la amida hidrolasa de acido graso.
JP2008529519A (ja) 2005-02-10 2008-08-07 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 脂肪酸アミドヒドロラーゼ分析
EP1866314B1 (en) * 2005-02-16 2010-09-15 NeuroSearch A/S Novel diazabicyclic aryl derivatives and their medical use
ES2433290T3 (es) 2005-02-17 2013-12-10 Astellas Pharma Inc. Derivados de piperazina para el tratamiento de la incontinencia urinaria y el dolor
US20090082435A1 (en) 2005-04-28 2009-03-26 The Regents Of The University Of California Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
WO2006129842A1 (ja) 2005-06-01 2006-12-07 Banyu Pharmaceutical Co., Ltd. オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
WO2006137465A1 (ja) 2005-06-24 2006-12-28 Shionogi & Co., Ltd. 含窒素複素環誘導体
PE20070099A1 (es) 2005-06-30 2007-02-06 Janssen Pharmaceutica Nv N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso
AU2006264649A1 (en) 2005-06-30 2007-01-11 Prosidion Limited GPCR agonists
CN101296914B (zh) 2005-08-26 2012-07-18 盐野义制药株式会社 具有ppar激动活性的衍生物
US7131609B1 (en) 2005-08-31 2006-11-07 Kimberly-Clark Worldwide, Inc. Dispenser for sheet material
AU2006332675A1 (en) 2005-12-29 2007-07-12 N.V. Organon Inhibitors of fatty acid amide hydrolase
US20070155707A1 (en) 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Ionizable inhibitors of fatty acid amide hydrolase
WO2007103456A2 (en) 2006-03-06 2007-09-13 Trimeris, Inc. Piperazine and piperidine biaryl derivatives
TW200811157A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators I
WO2008005368A2 (en) 2006-06-30 2008-01-10 Abbott Laboratories Piperazines as p2x7 antagonists
US20080045513A1 (en) 2006-08-18 2008-02-21 N.V. Organon Combination faah inhibitor and analgesic, anti-inflammatory or anti-pyretic agent
WO2008024139A2 (en) 2006-08-18 2008-02-28 N.V. Organon Inhibitors of fatty acid amide hydrolase
US7888394B2 (en) 2006-08-21 2011-02-15 N.V. Organon Synthesis, polymorphs, and pharmaceutical formulation of FAAH inhibitors
WO2008023720A1 (fr) 2006-08-23 2008-02-28 Astellas Pharma Inc. COMPOSÉ D'URÉE OU SEL DUDIT COMPOSé
WO2008030752A2 (en) 2006-09-07 2008-03-13 N.V. Organon Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
US20090099240A1 (en) 2006-10-02 2009-04-16 N.V. Organon Methods for treating energy metabolism disorders by inhibiting fatty acid amide hydrolase activity
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
DK2076508T3 (da) 2006-10-18 2011-02-21 Pfizer Prod Inc Biaryl-ether-urinstof-forbindelser
EP2096915A1 (en) 2006-11-20 2009-09-09 N.V. Organon Metabolically-stabilized inhibitors of fatty acid amide hydrolase
NZ552238A (en) 2006-12-20 2009-07-31 Seperex Nutritionals Ltd An extract
CA2688343A1 (en) 2007-05-25 2008-12-18 Janssen Pharmaceutica N.V. Heteroaryl-substituted urea modulators of fatty acid amide hydrolase

Also Published As

Publication number Publication date
RS20090154A (en) 2010-10-31
KR20090061051A (ko) 2009-06-15
ATE493984T1 (de) 2011-01-15
ME01308B (me) 2013-12-20
CN101595102A (zh) 2009-12-02
RS51647B (en) 2011-10-31
AP2009004821A0 (en) 2009-04-30
BRPI0717596A2 (pt) 2013-10-29
EP2076508B1 (en) 2011-01-05
DK2076508T3 (da) 2011-02-21
NO342266B1 (no) 2018-04-30
ZA200902548B (en) 2010-03-31
EP2076508A2 (en) 2009-07-08
DE602007011793D1 (de) 2011-02-17
PT2076508E (pt) 2011-03-07
CA2663984C (en) 2012-02-21
US20080261941A1 (en) 2008-10-23
UY30649A1 (es) 2008-05-31
HK1139652A1 (en) 2010-09-24
IL197664A (en) 2013-01-31
MY145460A (en) 2012-02-15
TN2009000138A1 (fr) 2010-10-18
TW200825062A (en) 2008-06-16
NZ575624A (en) 2012-02-24
IL197664A0 (en) 2009-12-24
CR20140313A (es) 2014-07-28
KR101181194B1 (ko) 2012-09-18
PL2076508T3 (pl) 2011-05-31
CN101595102B (zh) 2013-08-07
AU2007311591A1 (en) 2008-04-24
WO2008047229A3 (en) 2008-09-04
GEP20125425B (en) 2012-03-26
AR063331A1 (es) 2009-01-21
WO2008047229A2 (en) 2008-04-24
HRP20110158T1 (hr) 2011-04-30
HN2007000407A (es) 2010-10-04
CA2663984A1 (en) 2008-04-24
CR10701A (es) 2009-04-30
AU2007311591B2 (en) 2010-10-07
AP2780A (en) 2013-09-30
SI2076508T1 (sl) 2011-04-29
JP2010506896A (ja) 2010-03-04
MX2009004233A (es) 2009-08-12
ES2357340T3 (es) 2011-04-25
NO20091560L (no) 2009-05-15
TWI404715B (zh) 2013-08-11
BRPI0717596B1 (pt) 2020-04-14
US8044052B2 (en) 2011-10-25
PE20081265A1 (es) 2008-09-17
BRPI0717596B8 (pt) 2021-05-25
MA30801B1 (fr) 2009-10-01
EA200970296A1 (ru) 2009-10-30
CL2007003000A1 (es) 2008-06-13
JP4434313B2 (ja) 2010-03-17
EA015488B1 (ru) 2011-08-30

Similar Documents

Publication Publication Date Title
CY1111170T1 (el) Ενωσεις διαρυλ αιθερα ουριας
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
CY1119730T1 (el) Παραγωγα καρβοξυλικου οξεος πυρρολιδινης ως αγωνιστες του συζευγμενου με πρωτεϊνή-g υποδοχεα 43 (gpr43), φαρμακευτικη συνθεση και μεθοδοι για χρηση στην αντιμετωπιση μεταβολικων διαταραχων
EA201001733A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
CO6311079A2 (es) Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
RS53617B1 (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
EA201000436A1 (ru) Стероидные [3,2-с]пиразольные соединения, обладающие глюкокортикоидной активностью
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE484504T1 (de) Imidazo ä1,2-aüpyridin-2-carboxamid-derivate, herstellungsverfahren und ihre verwendung für therapeutika
CY1111733T1 (el) Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
TW200745122A (en) New compounds I
ATE495171T1 (de) Benzimidazoloncarbonsäureamidverbindungen als agonisten des 5-ht4-rezeptors
BR112014006763A2 (pt) n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
MA31567B1 (fr) Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique
ATE466007T1 (de) 5-substituierte indol-2-carbonsäureamidderivate
MX2011013869A (es) Agentes antihelminticos y su uso.
ATE444069T1 (de) Chinolin-derivate zur behandlung von mglur5- rezeptor-vermittelten erkrankungen
TW200745133A (en) New compounds II
TW200800966A (en) Beta-secretase modulators and methods of use
ATE474574T1 (de) Imidazoazephinonverbindungen
ATE517900T1 (de) Heptarylen-und octarylentetracarbonsäurediimide und deren herstellung